B. Braun Medical SAS announced as acquirer of Stimatix assets
In November 2014, Stimatix sold its assets to a subsidiary company of the B. Braun Group, B. Braun Medical SAS. The Asset Purchase Agreement (APA) included a nondisclosure agreement that prevented release of information; however, with an international market launch of the Stimatix product planned for mid-2018, B. Braun authorized disclosure by Trendlines of the fact that B. Braun was the acquirer. B. Braun Medical SAS is the location of the company’s Stoma Care Center of Excellence.
B. Braun, one of the world’s leading providers and manufacturers of health care solutions, is in the process of completing a high-volume manufacturing facility for the production of the Stimatix products.
Trendlines maintains a 28.2% holding in Stimatix. As of the last valuation (31 December 2017), the fair value of Trendlines’ Stimatix holding was $42.6 million. Stimatix is the company referred to in Trendlines’ financial statements and other reports as the “Most Valuable Portfolio Company.”
Read the full announcement about B. Braun’s acquisition of Stimatix’s assets.